The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data

Spanggaard, Maria; Bøgelund, Mette; Dirksen, Carsten; Jørgensen, Nils B.; Madsbad, S; Panton, Ulrik Haagen; Pedersen, Mikkel H; Reitzel, Signe Baattrup; Johansen, Pierre

doi:10.1080/14737167.2022.2053676

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 Besides detrimental health effects, it is negatively affecting society's economic landscape. 6 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Rubinić,

Kurtov,

Likić

2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy. Ghrelin, peptide YY (PYY), cholecystokinin (CCK), and amylin are crucial in appetite regulation offering promising targets for pharmacological interventions in obesity treatment using both peptide‐based and small molecule‐based pharmaceuticals. Ghrelin, a sole orexigenic gut peptide, has a potential for anti‐obesity therapies through various approaches, including endogenous ghrelin neutralization, ghrelin receptor antagonists, ghrelin O‐acyltransferase, and functional inhibitors. Anorexigenic gut peptides, peptide YY, cholecystokinin, and amylin, have exhibited appetite‐reducing effects in animal models and humans. Overcoming substantial obstacles is imperative for translating these findings into clinically effective pharmaceuticals. Peptide YY and cholecystokinin analogues, characterized by prolonged half‐life and resistance to proteolytic enzymes, present viable options. Positive allosteric modulators emerge as a novel approach for modulating the cholecystokinin pathway. Amylin is currently the most promising, with both amylin analogues and dual amylin and calcitonin receptor agonists (DACRAs) progressing to advanced stages of clinical trials. Despite persistent challenges, innovative pharmaceutical strategies provide a glimpse into the future of anti‐obesity therapies.

show abstract

“… 5 Besides detrimental health effects, it is negatively affecting society's economic landscape. 6 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Rubinić,

Kurtov,

Likić

2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

Ten‐year progression of obesity‐related complications in a population with overweight and obesity in the UK: A retrospective open cohort study

Pearson‐Stuttard,

Holloway,

Sommer Matthiessen

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo assess the prevalence of individual obesity‐related complications (ORCs) and multimorbidity (≥ 1, ≥ 2 and ≥ 3 ORCs), and multimorbidity‐associated healthcare costs, over 10 years.MethodsThis retrospective open cohort study used Discover, a UK database of linked primary and secondary electronic health records. Adults were stratified by body mass index (BMI; overweight: 25‐< 30 kg/m2; obesity class I: 30‐< 35 kg/m2; obesity class II: 35‐< 40 kg/m2; obesity class III: ≥ 40 kg/m2). Outcomes by year since baseline were assessed for serial cross sections across the study period (1 January 2004 to 31 December 2019; the index date was the date of first eligible BMI measurement).ResultsAcross 1 410 146 individuals (overweight: 1 008 101; obesity class I: 278 782; obesity class II: 80 621; obesity class III: 42 642), ORC prevalence was higher in successive BMI groups, and increases over time were generally greater for obesity relative to overweight. In those with ORC multimorbidity, both higher BMI and the presence of more ORCs were associated with higher annual per‐person healthcare costs. Costs increased over time in those individuals with obesity and one or more ORC, as well as in those with obesity and two or more ORCs.ConclusionsHigher BMI was associated with higher baseline ORC prevalence and a greater increase in ORC prevalence over time, and with higher healthcare costs in those with multimorbidity. To reduce the burden of overweight and obesity on patients and healthcare systems, the presence, number and type of ORCs should be considered in developing effective, targeted prevention and management care pathways.

show abstract

Anti‐obesity potential of Polygonum minus Huds.: in vitro and in vivo evaluation

Arshad,

Sofian‐Seng,

Afzan

et al. 2024

Int J of Food Sci Tech

View full text Add to dashboard Cite

SummaryPolygonum minus (PM) has a rich traditional usage for health benefits, yet its potential as a natural‐based solution for obesity management remains unexplored. This study evaluated the antioxidant properties, inhibition of pancreatic lipase and α‐glucosidase activities, and metabolite profiles of PM aerial extracts harvested at 8, 10, and 12 weeks using 1H NMR‐based metabolomics. PM harvested at 12 weeks exhibited significant antioxidant and enzyme inhibition activities. NMR metabolomics unveiled nine major metabolites correlated to the bioactivities of 12‐week PM. LC–MS/MS profiling enabled the identification of flavonoids and phenolic acids, with the majority having sulfate, gallate, and glycoside moieties. Notably, in vivo experiments demonstrated that rats treated with 200 mg kg−1 and 400 mg kg−1 PM exhibited significantly lower (P < 0.05) total body weight gain (39.03% and 52.59%, respectively) compared to negative control rats (69.95%), with the lower dose group also exhibiting reduced (P < 0.05) fasting blood glucose levels. This study highlights the potential of 12‐week PM as a natural‐based solution in obesity management.

show abstract

The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data

Cited by 3 publications

References 29 publications

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Ten‐year progression of obesity‐related complications in a population with overweight and obesity in the UK: A retrospective open cohort study

Anti‐obesity potential of Polygonum minus Huds.: in vitro and in vivo evaluation

Contact Info

Product

Resources

About